VOLC (MM)

SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, today reported results for the third quarter and first nine months of 2014.

For the quarter ended September 30, 2014, Volcano reported revenues of $97.5 million versus revenues of $95.8 million in the same period a year ago. Foreign currency had a negative impact on revenues of approximately $700,000. Medical segment revenues increased approximately two and three percent on a reported and constant currency basis, respectively.

The company reported a net loss on a GAAP basis of $8.0 million, or $0.16 per share, in the third quarter of 2014, versus a net loss of $8.5 million, or $0.15 per share, in the same period a year ago. The results for the third quarter of 2014 included amortization of intangibles of $2.8 million and  restructuring  benefits of $229,000 while the results for the third quarter of 2013 included amortization of intangibles of $834,000 and restructuring charges of $4.6 million. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP net loss of $0.04 per share, compared with a non-GAAP net loss per share of $0.08 in the third quarter a year ago.

For the first nine months of 2014, Volcano reported revenues of $294.6 million versus revenues of $290.4 million in the first nine months of 2013. On a constant currency basis, revenues increased three percent year-over-year after adjusting for a negative impact of approximately $3.4 million from foreign currency. Medical segment revenues increased approximately two and three percent on a reported and constant currency basis, respectively, versus the first nine months of 2013.

For the first nine months of 2014, the company reported a net loss on a GAAP basis of $18.6 million, or $0.36 per share, versus a net loss of $14.0 million, or $0.26 per share, in the same period a year ago. The results for the first nine months of 2014 included acquisition-related benefits of $3.8 million, amortization of intangibles of $6.4 million and  restructuring benefits of $197,000. The results for the first nine months of 2013 included acquisition-related charges of $3.7 million, amortization of intangibles of $2.5 million and restructuring charges of $4.9 million. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP net loss of $0.14 per share in the first nine months of 2014, compared with a non-GAAP net loss per share of $0.03 in the first nine months of 2013.

"We continued to demonstrate strong growth in Europe, where our FFR (Fractional Flow Reserve) and IVUS (Intravascular Ultrasound) disposable revenues each increased 24 percent year-over-year," said Scott Huennekens, president and chief executive officer.

"In addition, our peripheral IVUS business in the U.S. increased approximately 60 percent, driven by continued adoption of our peripheral imaging and Pioneer® Re-Entry products. We also initiated the  limited market release of our Phoenix® Atherectomy System used in the treatment of peripheral artery disease, which we believe will advance our overall penetration of the peripheral market. Our growth in these areas helped offset the continued softness of the U.S. coronary IVUS market," he added.

"At the same time, we are successfully implementing an operating strategy as we execute a more balanced approach between driving revenue growth and improving our bottom line performance. As evidenced by our third quarter results and guidance for the balance of the year, we have made measurable success in reducing operating expenses and will be taking additional steps to achieve improved operating leverage," Huennekens noted.

Guidance

The company provided updated guidance for the full year 2014. The company expects that based on current foreign currency exchange rates, FX will have a negative impact of approximately $4.0 million on reported revenues through the balance of the year. As a result, the company now expects revenues for 2014 will be in the range of $393.0-$397.0 million. The company expects gross margins will be 63.0-63.5 percent and that operating expenses, including restructuring charges, will be 65.0-66.0 percent of revenues. As a result of continued expense management programs contributing to lower operating expenses as a percentage of revenues, the company now expects a two cent improvement in its loss per share on a GAAP basis, or a loss per share of $0.50-$0.52. On a non-GAAP basis, the company expects a loss of $0.16-$0.18 per share. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense, and assume an effective tax rate of 35.0 percent for the GAAP to non-GAAP adjustments. The company expects weighted average basic shares in 2014 will be approximately 51.6 million.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time) today. The teleconference can be accessed by calling (631) 291-4555, passcode 17203481, or via the company's website at http://www.volcanocorp.com. Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through November ninth, at (404) 537-3406, passcode 17203481, and via the company's website at http://www.volcanocorp.com.

About Volcano Corporation

Through its multi-modality platform, Volcano Corporation is the global leader in intravascular imaging for coronary and peripheral applications, and physiology. The company also offers a suite of peripheral therapeutic devices. The company's broad range of technologies makes imaging and therapy simpler, more informative and less invasive and offers physicians and their patients around the world with industry-leading tools that aid diagnosis and guide and provide therapy. Founded in cardiovascular care and expanding into other specialties, Volcano is focused on improving patient and economic outcomes. For more information, visit the company's website at www.volcanocorp.com.

Notes Regarding the Use of Non-GAAP Financial Measures

The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The company uses non-GAAP financial measures for financial and operational decision making as a measure to compare period-to-period results. The company believes that they provide useful information about operating results, enhance the overall understanding of operating results and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Constant Currency Basis Revenues Changes: Volcano reports changes on a constant currency basis, which is a non-GAAP financial measure. Volcano believes that investors' understanding of the company's short-term and long-term financial results is enhanced by taking into consideration the impact of foreign currency translation on revenues. In addition, Volcano's management uses results of operations before currency translation to evaluate the operational performance of Volcano and as a basis for strategic planning.

Volcano reports its expectations of earnings per share performance excluding certain expenses described below; for additional details please see the "Reconciliation of GAAP to non-GAAP EPS Guidance," table in this press release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.

Exclusion of Acquisition-Related Expenses: Volcano excludes acquisition-related expenses because it does not consider these acquisition-related costs and adjustments to be related to the continuing organic operations of the acquired businesses and are generally not relevant to assessing or estimating the long-term performance of the acquired assets. In addition, the size, complexity and/or volume of past acquisitions, which often drive the magnitude of acquisition-related costs, may not be indicative of the size, complexity and/or volume of future acquisitions.

Exclusion of Amortization of Intangibles: Volcano excludes amortization of intangibles because it is a non-cash expense relating primarily to acquisitions. At the time of an acquisition, the intangible assets of the acquired company, which consist primarily of developed or in-process technology, are valued and amortized over their estimated lives. Volcano believes that since intangible assets represent efforts of the acquired company to build value prior to the acquisition, Volcano management eliminates the impact of the amortization when evaluating its current operating performance.

Exclusion of Non-Cash Interest Expenses: In addition to disclosing the financial statement impact of the authoritative guidance for convertible debt accounting, Volcano management believes that excluding the impact of this authoritative guidance is appropriate because it is non-cash in nature, may provide meaningful supplemental information regarding elements of the company's borrowing costs in order to properly understand its operational performance and liquidity, and facilitates comparisons to competitors' results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding Volcano's expected revenues, revenue growth, margins, financial results and foreign currency exchange rates for the fourth quarter and calendar year 2014, its growth, turnaround and other strategies and ability to execute on these strategies, the potential Axsun divestiture, competitive position, target markets, development of its base business and pipeline, product launches, benefits from recent acquisitions and benefits from its products and technologies, including new products. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risks that Volcano's revenues or other projections may turn out to be inaccurate or Volcano may encounter unanticipated difficulty in achieving these projections; global and regional macroeconomic conditions, generally, and in the medical device and telecom industries, specifically; currency exchange rate fluctuations; the effect of competitive factors and the company's reactions to those factors; purchasing decisions with respect to the company's products; the pace and extent of market adoption of the company's products and technologies; uncertainty in the process of obtaining regulatory approval or clearances for Volcano's products or devices; the success of Volcano's growth and other strategies, including the integration of recently-acquired businesses and our ability to integrate businesses from potential future acquisitions; risks associated with Volcano's international operations; the ability to divest Axsun, if at all, and in a timely or beneficial manner; timing and achievement of product development milestones; outcome of ongoing and future litigation, investigations or claims; the impact and benefits of market development and the related size of Volcano's addressable markets; our ability to protect our intellectual property; dependence upon third parties; unexpected new data, safety and technical issues; market conditions and other risk inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are fully described in Volcano's filings made with the Securities and Exchange Commission, including our 10-Q for the quarter ended June 30, 2014, which should be read in conjunction with these financial results. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation